Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis

<p><strong><i>Introduction:</strong></i> This study evaluated the efficacy of the interleukin-17A inhibitor secukinumab in patients with oligoarticular psoriatic arthritis (PsA).</p> <p><strong><i>Methods:</strong></i> A total of 84...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Ogdie, A, Gladman, DD, Coates, LC, Pournara, E, Parikh, B, Mease, PJ
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	Springer 2023

Míreanna comhchosúla

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
de réir: Alexis Ogdie, et al.
Foilsithe / Cruthaithe: (2023-05-01)

Measuring outcomes in psoriatic arthritis
de réir: Ogdie, A, et al.
Foilsithe / Cruthaithe: (2020)

Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
de réir: Gossec, L, et al.
Foilsithe / Cruthaithe: (2024)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
de réir: Gladman, DD, et al.
Foilsithe / Cruthaithe: (2018)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
de réir: Strand, V, et al.
Foilsithe / Cruthaithe: (2022)

Psoriatic arthritis
de réir: FitzGerald, O, et al.
Foilsithe / Cruthaithe: (2021)

Psoriatic arthritis: prospects for the future
de réir: Hackett, S, et al.
Foilsithe / Cruthaithe: (2022)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
de réir: Helliwell, PS, et al.
Foilsithe / Cruthaithe: (2022)

Classification and outcome measures for psoriatic arthritis
de réir: Leung, Y, et al.
Foilsithe / Cruthaithe: (2018)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
de réir: Mease, PJ, et al.
Foilsithe / Cruthaithe: (2020)

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis
de réir: Leung, YY, et al.
Foilsithe / Cruthaithe: (2020)

Classification and Outcome Measures for Psoriatic Arthritis
de réir: Ying Ying Leung, et al.
Foilsithe / Cruthaithe: (2018-09-01)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
de réir: Orbai, A-M, et al.
Foilsithe / Cruthaithe: (2019)

Methotrexate in psoriasis and psoriatic arthritis
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2020)

BIOLOGIC THERAPY OF PSORIATIC ARTHRITIS
de réir: D.D. Gladman
Foilsithe / Cruthaithe: (2011-09-01)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
de réir: Tillett, W, et al.
Foilsithe / Cruthaithe: (2017)

Psoriatic arthritis: prospects for the future
de réir: Simon Hackett, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2020)

Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review
de réir: Leung, Y-Y, et al.
Foilsithe / Cruthaithe: (2020)

Th17 and Th1 Lymphocytes in Oligoarticular Juvenile Idiopathic Arthritis
de réir: Laura Maggi, et al.
Foilsithe / Cruthaithe: (2019-03-01)

Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership: Recommended next steps
de réir: Tillett, W, et al.
Foilsithe / Cruthaithe: (2020)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
de réir: Baraliakos, X, et al.
Foilsithe / Cruthaithe: (2022)

Considerations for the definition of remission criteria in psoriatic arthritis
de réir: Mease, P, et al.
Foilsithe / Cruthaithe: (2017)

Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis
de réir: Leung, YY, et al.
Foilsithe / Cruthaithe: (2021)

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study
de réir: Petersen, MB, et al.
Foilsithe / Cruthaithe: (2023)

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial
de réir: Strand, V, et al.
Foilsithe / Cruthaithe: (2024)

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
de réir: Coates, LC, et al.
Foilsithe / Cruthaithe: (2023)

The GRAPPA-OMERACT Working Group: 4 prioritized domains for completing the core outcome measurement set for psoriatic arthritis 2019 updates
de réir: Leung, YY, et al.
Foilsithe / Cruthaithe: (2020)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
de réir: Mease, PJ, et al.
Foilsithe / Cruthaithe: (2019)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
de réir: Gladman, DD, et al.
Foilsithe / Cruthaithe: (2022)

USE OF ETANERCEPT IN PATIENTS WITH OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
de réir: Т. М. Bzarova, et al.
Foilsithe / Cruthaithe: (2014-12-01)

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
de réir: Pournara, E, et al.
Foilsithe / Cruthaithe: (2021)

Interleukin 17A inhibitor secukinumab in the treatment of patients with psoriatic arthritis
de réir: N. A. Shostak, et al.
Foilsithe / Cruthaithe: (2022-10-01)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
de réir: Nash, P, et al.
Foilsithe / Cruthaithe: (2021)

Sex-specific differences in patients with psoriatic arthritis: a systematic review
de réir: Coates, LC, et al.
Foilsithe / Cruthaithe: (2022)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
de réir: Philip J. Mease, et al.
Foilsithe / Cruthaithe: (2024-01-01)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
de réir: Weinstein, SM, et al.
Foilsithe / Cruthaithe: (2021)

Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1 year results from two phase 3 studies
de réir: Gossec, L, et al.
Foilsithe / Cruthaithe: (2024)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2019)

Hot topice debate: preventing psoriatic arthritis in patients with psoriasis
de réir: Vivekanantham, A, et al.
Foilsithe / Cruthaithe: (2024)